Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute ...

Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Alkermes wants to augment its pipeline with M&A or licensing deals in serious mental illnesses and substance abuse. “I think anyone who's developing a drug in these spaces, they are probably better ...

The “key” to the narcolepsy type 1 asset ... the company expects its drug “will have a much higher efficacy" than the current TYK2 inhibitor on the market, Weber said.

Drugmakers raised the list prices on 575 name-brand drugs in just the first two days of the new year, according to drug price research firm 46brooklyn. Drugs for diabetes, HIV, cancer saw price ...

“People with narcolepsy, the drugs they’ve been using to treat their condition have basically been blunt instruments,” Pops said of the current array of stimulants and sedatives that treat ...

The four major Medicare parts (A, B, C, D) all offer some prescription drug coverage. Medicare Part D offers the most extensive outpatient prescription drug coverage ...

And even though Jazz Pharmaceuticals (JAZZ) is a formidable competitor with its low sodium, twice nightly narcolepsy drug Xywav, all these problems sound like Lumryz problems, and overall ...

Sales of its narcolepsy drug, LUMRYZ rose by 150% YoY. AVDL expects net product revenue for 2025 in the range of $240 million to $260 million. Get the Real Story Behind Every Major Earnings Report ...

DUBLIN - Avadel Pharmaceuticals plc (NASDAQ: NASDAQ:AVDL), a company specializing in the development of transformative medicines with a market capitalization of $1.05 billion, has announced ...